<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02843958</url>
  </required_header>
  <id_info>
    <org_study_id>38RC14.008</org_study_id>
    <nct_id>NCT02843958</nct_id>
  </id_info>
  <brief_title>Validation of a Portable Medical Device for Diagnostic in Vitro</brief_title>
  <acronym>HEMOPTIC</acronym>
  <official_title>Validation of a Portable Medical Device for Diagnostic in Vitro, Designed to Measure Blood Coagulation's Biological Parameters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is about a new technology, named HEMOPTIC. It enables to mesure time of
      blood coagulation for monitoring of patients under Vitamin K antagonist (VKA).

      This device was created as an alternative to blood sample, that have to be done in a medical
      laboratory.

      The main goal is to evaluate the accuracy of the International Normalized Ratio (INR)
      measurement of this new portable device for diagnostic in vitro, among healthy patients and
      patients under anti-vitamin K treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>International Normalized Ratio measurement: comparison to the standard reference.</measure>
    <time_frame>V2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>International Normalized Ratio measurement: repeatability</measure>
    <time_frame>V2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Normalized Ratio measurement:reproductibility</measure>
    <time_frame>V2</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Volunteer</condition>
  <condition>Patients Under Vitamin K Antagonist (VKA)</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers and patients under Vitamin K antagonist</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HEMOPTIC</intervention_name>
    <arm_group_label>Healthy volunteers and patients under Vitamin K antagonist</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria of healthy volunteers:

          -  Man or woman between 18 and 70 years

          -  Body Mass Index &gt;18 and &lt;29

          -  Absence of any acute pathology in the month preceding the study

          -  To be affiliated or beneficiary of social security

        Exclusion Criteria of healthy volunteers:

          -  Pregnant, partutient or breastfeeding woman

          -  Patient with Raynaud's syndrome

          -  Person deprived of liberty by legal or administrative decision, person to a legal
             protection order

          -  Deferral periods for other clinical studies

          -  Annual threshold compensation attain for biomedical search participations

        Inclusion Criteria of patients:

          -  Man or woman between 18 and 80 years

          -  Patient treated by oral anti vitamin K anticoagulants (coumadine, warfarine,
             fluidione)

          -  Absence of any acute pathology in the month preceding the study

          -  To be affiliated or beneficiary of social security

        Exclusion Criteria of healthy patients:

          -  Pregnant, partutient or breastfeeding woman

          -  Patient with Raynaud's syndrome

          -  Person deprived of liberty by legal or administrative decision, person to a legal
             protection order

          -  Deferral periods for other clinical studies

          -  Annual threshold compensation attain for biomedical search participations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Luc Cracowski, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grenoble Hospital University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UniversityHospitalGrenoble</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet. 2006 Feb 4;367(9508):404-11. Review.</citation>
    <PMID>16458764</PMID>
  </reference>
  <reference>
    <citation>Faivre M, Peltié P, Planat-Chrétien A, Cosnier ML, Cubizolles M, Nougier C, Négrier C, Pouteau P. Coagulation dynamics of a blood sample by multiple scattering analysis. J Biomed Opt. 2011 May;16(5):057001. doi: 10.1117/1.3573813.</citation>
    <PMID>21639579</PMID>
  </reference>
  <reference>
    <citation>Matchar DB, Jacobson A, Dolor R, Edson R, Uyeda L, Phibbs CS, Vertrees JE, Shih MC, Holodniy M, Lavori P; THINRS Executive Committee and Site Investigators. Effect of home testing of international normalized ratio on clinical events. N Engl J Med. 2010 Oct 21;363(17):1608-20. doi: 10.1056/NEJMoa1002617. Erratum in: N Engl J Med. 2011 Jan 6;364(1):93.</citation>
    <PMID>20961244</PMID>
  </reference>
  <reference>
    <citation>McBride GB (2005) A proposal for strength-of-agreement criteria for Lin's Concordance Correlation Coefficient. NIWA Client Report: HAM2005-062.</citation>
  </reference>
  <reference>
    <citation>Riberolles, C. (2009). Résultats du PHRC autocontôle de l'anticoagulation. Conférence. XIXes Journées européennes de la Société française de cardiologie, Paris.</citation>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>July 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2016</study_first_posted>
  <last_update_submitted>September 29, 2016</last_update_submitted>
  <last_update_submitted_qc>September 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Medical device</keyword>
  <keyword>Hemoptic</keyword>
  <keyword>Vitamin K antagonist</keyword>
  <keyword>Diagnostic in vitro</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin K</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

